drugset / Trial / NCT02901925
A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
Phase 0
Completed
14 enrolled
Dartmouth-Hitchcock Medical Center
Dartmouth College · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The primary study objective is to determine if microdoses of ABY-029 lead to detectable signals in sampled tissues with an EGFR pathology score ≥ 1 based on histological staining. The secondary study objective is to assess diagnostic accuracy of ABY-029 detection by iFI and intraoperative probe relative to histopathology diagnosis, and other indicators (e.g. proliferation, infiltration, etc.) as the gold standard, and to measure the molecular uptake and concentration of ABY-029 in resected specimens.
Timeline
- Start
- 2017-02-13
- Primary completion
- 2021-06-29
- Completion
- 2021-06-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABY-029 | Peptide | — | Intravenous |